Sage Therapeutics Inc (NAS:SAGE)
$ 11.09 0.46 (4.31%) Market Cap: 669.82 Mil Enterprise Value: -72.17 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 46/100

SAGE Therapeutics Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript

Dec 09, 2020 / 08:00PM GMT
Release Date Price: $69.19 (-2.34%)
Gary Jay Nachman
BMO Capital Markets Equity Research - Analyst

Hi, everyone. I'm Gary Nachman, the biopharma analyst at BMO. We're really excited to have Sage management with us participating in BMO's Growth and ESG Conference. We have Steve Kanes, Chief Medical Officer; Mike Cloonan, Chief Operating Officer.

This is a really exciting time for you guys, particularly with the recent Biogen collaboration. So it's great to have you here to give us the updates on all your progress. So thanks for your time today.

Michael Cloonan
Sage Therapeutics, Inc. - COO

Thanks, Gary. Great to be here.

Questions & Answers

Gary Jay Nachman
BMO Capital Markets Equity Research - Analyst

Good. So since there are some investors listening in that may not be as familiar with your story, describe what the company's overall strategy has been with respect to drug development in CNS and what your key strengths are in that area. And then with the recent transformational collaboration with Biogen that you just announced for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot